secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001193125-24-189569
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's
--------------------------------------------------------------------------------

- Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.
- Secondary endpoint: statistically significant increase in FDG-PET signal in medial temporal cortex (p=0.0297) in MCI patients over 12 months.
- Results echo prior Phase 2 Huntington's data, suggesting similar mechanism targeting astrocyte activation.
- Company actively pursuing a pharmaceutical partner for late-stage development in Alzheimer's disease.
- Pepinemab has been well-tolerated in over 600 patients across AD, HD, and MS trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312524189569/0001193125-24-189569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312524189569/d858316d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-189569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer